DelMar Pharma begins dosing in Phase II trial of VAL-083 to treat GBM

Biopharmaceutical firm DelMar Pharmaceuticals has begun dosing in a Phase II clinical trial of VAL-083 for the treatment of MGMT-unmethylated Avastin (bevacizumab)-na ï ve recurrent glioblastoma multiforme (GBM).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news